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Abstract 
Background: Prostate cancer (PCa), a major cause of cancer‑related morbidity and mortality worldwide and mostly 
asymptomatic at earliest stages, is characterized by disruption of genetic and epigenetic balance. A better under‑
standing of how those mechanisms orchestrate disease might improve diagnostic and prognostic tools, allowing for 
improvements in treatment efficacy. Replacement of canonical histones, an epigenetic mechanism, is highly con‑
served among species and altered expression of histones variants (e.g., MacroH2A1) has been associated with tumo‑
rigenesis. H2AFY gene encodes two isoforms of H2A histone variant MacroH2A1: MacroH2A1.1 and MacroH2A1.2. 
Specifically, MacroH2A1.1 isoform inhibits cell proliferation and promotes cellular differentiation. Because the contri‑
bution of this histone variant to carcinogenesis has been reported in several cancer types, but not for PCa, we aimed 
to investigate the contribution of MacroH2A1 for prostate carcinogenesis.
Methods: MacroH2A1, MacroH2A1.1 and MacroH2A1.2 isoforms and the corresponding splicing regulators transcript 
levels were evaluated by RT‑qPCR, in a tissue cohort composed by PCa, prostatic intraepithelial neoplasia (PIN) and 
normal prostate cases. Knockdown for MacroH2A1 and MacroH2A1.1 was performed through lentiviral transduction 
in DU145 cells, and MacroH2A1.1 overexpression was achieved in LNCaP cells by plasmid transfection, followed by 
functional assays. Biological and/or experimental replicates were performed when necessary, and specific statistical 
tests were applied to perform data analysis.
Results: MacroH2A1.1 transcript levels were downregulated in PIN and primary PCa compared to normal prostate 
tissues. The same was found for QKI, a MacroH2A1.1’s splicing regulator. Moreover, lower MacroH2A1.1 and QKI 
expression levels associated with less differentiated tumors (Gleason score ≥ 7). Interestingly, MacroH2A1.1, but more 
impressively DDX17 (AUC = 0.93; p < 0.0001) and QKI (AUC = 0.94; p < 0.0001), accurately discriminated cancerous 
from noncancerous prostate tissues. Furthermore, in PCa cell lines, total MacroH2A1 knockdown augmented malig‑
nant features, whereas MacroH2A1.1 overexpression impressively attenuated the malignant phenotype.
Conclusions: Overall, our data, derived from primary PCa tissues and cell lines, anticipate a tumor suppressive role for 
MacroH2A1, particularly for the MacroH2A1.1 isoform, in prostate carcinogenesis.
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Background
Prostate cancer (PCa) is the most common non-cuta-
neous malignancy in men and a major cause of can-
cer-related morbidity and mortality worldwide [1]. 
Characteristically asymptomatic at its earliest stages, 
when curative-intended therapy is most likely to be suc-
cessful, PCa is characterized by a broad range of altera-
tions in both genetic and epigenetic level [2, 3].
Among epigenetic mechanisms deregulated in cancer, a 
relevance of changes in histone variants that can replace 
canonical histones (nowadays referred to as replication-
coupled histones) has just started to emerge while still 
being poorly understood [4, 5]. Unlike canonical his-
tones, variants display time-based incorporation at the 
nucleosomes, are tissue-specific and DNA replication-
independent [6]. The H2A family of histones comprises 
structurally diverse variants, including H2A.X, H2A.Z, 
MacroH2A1, H2A.Bb, characterized by distinct length, 
sequence and genome distribution [7, 8]. Deregula-
tion in H2A variants have been previously implicated in 
cancer [4]. The H2AFY gene encodes for MacroH2A1, a 
histone variant frequently found in repressed chromatin 
such as the inactive X chromosome in female cells [9, 10]. 
Moreover, a subset of genes positively regulated by Mac-
roH2A1 has also been reported [11–13]. MacroH2A1 
is present in Senescence-Associated Heterochromatic 
Foci [14], as well as on genes involved in cell cycle [15], 
pluripotency [16] and development [10, 17]. Addition-
ally, two isoforms of MacroH2A1—MacroH2A1.1 and 
MacroH2A1.2—result from the substitution of a single 
exon [4, 18]. MacroH2A1.1 is preferentially expressed 
over 1.2 in differentiated cells whereas MacroH2A1.2 is 
more expressed in proliferative cells [19, 20]. The ratio 
of MacroH2A1 isoforms expression levels is regulated 
by pre-mRNA splicing regulators. Indeed, without alter-
ing global MacroH2A1 expression, QKI promotes Mac-
roH2A1.1 expression, whilst MacroH2A1.2 expression is 
promoted by RNA helicases DDX5/DDX17 [21, 22].
Alterations in the expression of total MacroH2A1 or its 
isoforms [19] has been observed in several cancer types, 
including breast carcinoma [22, 23], melanoma [24], lung 
carcinoma [25] and colorectal carcinoma [26]. Taken 
the bulk literature together the MacroH2A1.1 isoform 
emerges as pleiotropic tumor suppressor, by repressing 
cell proliferation, migration and invasion, whereas the 
role of MacroH2A1.2 is largely cancer-type dependent 
[18, 27].
We have previously demonstrated that the histone H2A 
variant H2A.Z is upregulated in PCa [28], suggesting that 
the substitution of canonical histones by variants might 
be implicated in prostate carcinogenesis. As opposing 
functions for H2AZ and MacroH2A1 in gene regulation 
were reported in cancer cells [29], we investigated the 




Tumor samples from 197 Prostate cancer patients and 
45 PIN lesions were prospectively collected from radical 
prostatectomy specimens obtained from 2001 to 2006, 
at the Portuguese Oncology Institute of Porto, Portu-
gal. Among these, 34 patients had both PIN lesions and 
PCa samples. Immediately after surgery, specimens were 
fully sectioned and “twin fragments” were obtained, one 
for routine histopathological processing and the other 
was frozen and stored at − 80  °C. After full mapping of 
each prostate in FFPE tissue sections, the index tumor 
(the tumor nodule in multifocal disease that portrays 
the most relevant combination of prognostically relevant 
histo-morphological parameters, i.e., stage/local exten-
sion and grade) and PIN lesions were identified. Each 
PCa case was staged and the corresponding index tumor 
was scored according to the Gleason grading system 
[30]. Then, a frozen fragment corresponding to the index 
tumor and another corresponding to the PIN lesion were 
selected for RNA extraction. For that purpose, frozen 
sections were cut, and H&E stained for allowing for con-
firmation of the presence PIN lesions and index tumor, 
including Gleason score representability. Then, each tis-
sue fragment was trimmed to maximize the yield of tar-
get cells (> 70% of target cells) through serial cutting of 
thick (10 µm) sections. This procedure was performed by 
the same experienced uropathologist (RH) and allowed 
for confirmation that both PIN lesions and tumor areas 
identified in the frozen sections were representative of 
the index lesions identified in the routine assessment of 
the prostatectomy specimen. Relevant clinical data was 
retrieved from clinical charts. Fifteen samples of MNPT, 
used as controls, were obtained from the peripheral zone 
of prostates not harboring PCa, obtained from radi-
cal cystoprostatectomies performed for bladder cancer 
treatment that were submitted to the same procedure as 
prostate specimens that harbored cancer.
Prostate cancer cell lines
Benign prostate cell line RWPE-1 and PCa cell lines 
22Rv1, LNCaP and VCaP, which are androgen receptor 
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(AR) positive, as well as PCa cell lines DU145 and PC-3, 
characterized as AR negative, were grown for in  vitro 
assays. RWPE-1 cells were maintained in K-SFM 
growth medium supplemented with Bovine pituitary 
extract + Human recombinant epidermal growth factor 
and 1% penicillin/streptomycin. 22Rv1 and LNCaP cells 
were grown in RPMI 1640, DU145 and VCaP cells were 
maintained in MEM and PC-3 cells were grown in 50% 
RPMI-1640 + 50% F-12 medium  (GIBCO®). The culture 
media of PCa cell lines were supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin  (GIBCO®). 
Cells were grown in an incubator at 37 °C with 5%  CO2. 
All prostate cell lines were tested for Mycoplasma spp. 
contamination (PCR Mycoplasma Detection Set, Clon-
tech Laboratories). Cells later harvested for protein and 
RNA extraction.
RNA extraction and quantitative reverse transcription PCR 
(qRT‑PCR)
Samples were homogenized in  TRIzol® Reagent (Invitro-
gen) and the total RNA was extracted using PureLink™ 
RNA Mini Kit (Invitrogen). All genomic DNA was elimi-
nated with TURBO DNA-free (Ambion, Applied Bio-
systems), according to manufacturer’s instructions. First 
strand synthesis was performed using the  TransPlex® 
Whole Transcriptome Amplification Kit (Sigma-
Aldrich®) and QIAquick PCR Purification Kit (QIAGEN) 
for purification.
Target genes’ expression was determined using 
Fast SYBR  Green® Gene Expression Assay (Applied 
 Biosystems®) and normalized to the expression of the 
endogenous control β-glucuronidase (GUSB), a house-
keeping gene. Primers were MacroH2A1.1: forward, 
5′-GGC TTC ACA GTC CTC TCC AC-3′, and reverse, 
5′-GGT GAA CGA CAG CAT CAC TG-3′; MacroH2A1.2: 
forward, 5′- GGC TTC ACA GTC CTC TCC AC-3′, and 
reverse, 5′-GGA TTG ATT ATG GCC TCC AC-3′; Mac-
roH2A1: forward, 5′-TCC ATT GCA TTT CCA TCC ATC 
GGC -3′, and reverse, 5′-ACA CGA AGT AAC TGG AGA 
TGG CCT -3′; QKI: forward, 5′-ATT AAA CGG TCC CCT 
GAA GC-3′, and reverse, 5′-ATC AAC AGC CCA AGT 
GTG AC-3′; DDX5: forward, 5′-GTA GCT CAG ACT GGA 
TCT GG-3′, and reverse, 5′-TCT CTA GGA ATG GCT 
GGT GG-3′DDX17: forward, 5′-AGA AGT AGC AAG 
ACT GAC TCC -3′, and reverse, 5′-CCC CCT CTC ACT 
GTA ATC TC-3′; GUSB: forward, 5′-CTC ATT TGG AAT 
TTT GCC GATT-3′, and reverse, 5′-CCG AGT GAA GAT 
CCC CTT TTTA-3′; and H2AZ forward, 5′-GGG AAG 
AAA GGA CAA CAG -3′, and reverse, 5′-CAC AGA GAT 
ACA GTC CAC TGG-3′. RNA levels were determined by 
the standard curve method. All samples were analyzed 
in triplicate in a 7500 Real-Time PCR system (Applied 
 Biosystems®), and the mean value was used for data 
analysis.
Transfection of cell lines
DU145 cells, which showed the highest MacroH2A1.1 
expression levels, were selected for knocking-down 
assays. Thus, cells were transiently transfected with 
SMARTpool: siGENOME H2AFY siRNA (Dharma-
con) to knockdown MacroH2A1, and for MacroH2A1.1, 
cells were transiently transfected with a previously pub-
lished siRNA pool at 25  nM, and a siRNA negative 
control served as control in all experiments [22]. Oligo-
fectamine™ reagent (Invitrogen, USA) was used for trans-
fection under conditions indicated by the manufacturer. 
Cells were seeded 24 h before transfection, according to 
the purpose: for MTT assay, 4000 cells/well were seeded 
(96-well plates); apoptosis evaluation 30,000 cells/well 
were plated (24-well plates); and for RNA and protein, 
200,000 cells/well were used (6-well plates). The siRNA 
transfection was performed only once after cell seeding.
Overexpression of MacroH2A1.1 was achieved in 
LNCaP cells that depicted the lowest transcript levels. 
This was performed through pEZ-Lv105 (GeneCopoei-
aTM) using  FuGENE® HD Transfection Reagent (Pro-
mega), following manufacturer’s recommendations. After 
transfection, stable cell lines transfected with the vector 
and selected with puromycin dihydrochloride for in vitro 
assays. The stable cell lines generated where then use to 
test cell viability (MTT assay, 10,000 cells/well), apoptosis 
(50,000 cells/well), and for RNA and protein.
In both conditions, protein and RNA extraction was 
performed in cells harvested at 72 h.
SDS‑PAGE and western blot
Total protein was extracted from cell lines using the 
Kinexus Lysis Buffer with protease inhibitor (Kinexus 
Bioinformatics Corporation). Protein concentration was 
determined using Pierce BCA Protein Assay Kit (Thermo 
Scientific) following manufacturer’s instructions. Then, 
30 μg of total protein were separated by SDS-PAGE, blot-
ted in PVDF membranes (BioRad) and incubated in 5% 
(w/v) bovine serum albumin (BSA) blocking solution 
(ChemCruz™) for 1  h. Membranes were probed with 
antibodies against MacroH2A1.1 (#12,455, Cell Sign-
aling), MacroH2A1.2 (#4827; Cell Signaling), Cleaved 
PARP (Asp214) (19F4) (#9546, Cell Signaling) or the 
endogenous control β-actin (Sigma). Western Bright™ 
ECL-spray (Advansta) was used to develop the blots. 
Triplicates were performed in all experiments. Rela-
tive optical density determination was performed using 
ImageJ and normalized for the loading control, β-actin.
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Cell viability
Cell viability was assessed in transfected LNCaP and 
DU145 cells using the 3-(4, 5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium (MTT; Sigma-Aldrich®) assay. 
The viability assay was performed after cells adhered 
to the plate and, for DU145 cell line, right before trans-
fection (0  h) and in the subsequent days (24 and 48  h). 
MTT was added to the cells at 37  °C for 1  h, formazan 
crystals were dissolved in 100  μL of Dimethyl sulfoxide 
DMSO (Sigma-Aldrich®) and plates shaken for 15  min. 
Colorimetric quantification was performed in an auto-
mated plate reader  GloMax®-Multi Detection System 
(Promega) at 560 nm, with a reference filter of 630 nm. 
The optical density (OD) was directly proportional to the 
number of viable cells. Three biologically independent 
experiments and methodological triplicates were done 
for all experiments.
Apoptosis
APOPercentage™ kit (Biocolor) was used to evalu-
ate apoptotic levels using a multi-plate  GloMax®-Multi 
Detection System (Promega), for OD measurement of the 
released dye at 550 nm with a reference filter of 620 nm. 
To normalize the OD measured in the apoptotic test to 
the cell number, the OD of apoptosis was normalized to 
the OD of the viability assay. Three biological independ-
ent experiments were performed with methodological 
triplicates for each experiment.
Statistical analysis
Differences in quantitative expression levels of Mac-
roH2A1 and splicing regulators among MNPT, PIN and 
PCa were assessed using the non-parametric Kruskal–
Wallis test, followed by pairwise comparisons with 
Mann–Whitney U-test, with Bonferroni’s correction. 
Differences in gene expression between matched PIN and 
PCa samples were calculated by Wilcoxon Signed Rank 
test. Spearman’s correlation test was used to evaluate the 
association between transcript levels of different genes. 
The associations between expression levels and standard 
clinicopathological variables (serum PSA levels at diagno-
sis, Gleason score, histopathological stage) were assessed 
using the Kruskal–Wallis or Mann–Whitney tests, as 
appropriate. A receiver operator characteristic (ROC) 
curve, its area under the curve and respective confidence 
intervals, were constructed, as described in [30], to assess 
the performance of MacroH2A1.1 and splicing regulators 
expression for discriminating PCa from MNPT [31]. To 
demonstrate that the confidence intervals for the AUC 
obtained in this series (MNPT = 15 and PCa = 197) are 
statistically robust, a simulation study was performed 
(Additional file 1: Data S1). Moreover, for the same genes, 
biomarker sensitivity, specificity and accuracy param-
eters were calculated, as well as the positive (LR+) and 
negative (LR−) likelihood ratios. Regarding this, as the 
quantitative value of a calculated likelihood ratio is fur-
ther away from 1 in either direction (> 1 for LR+ and < 1 
for LR−), there is increasing utility of a diagnostic test to 
point toward, or away from, a diagnosis which indicate 
the value of performing the respective diagnostic tests. 
Correlation between MacroH2A1, respective isoforms 
and splicing regulators or H2A.Z expression levels were 
assessed by Spearman’s correlation coefficient (r).
In cell lines, fold variation differences in transcript and 
protein levels were determined using One-Way Analy-
sis of Variance (ANOVA), followed by Dunnet’s (post 
hoc) test for multiple comparisons, or unpaired t-test, as 
appropriate, comparing all PCa cell lines against RWPE-1 
or negative control of transfection.
All tests were two-sided and statistical significance 
was set at p < 0.05. Statistical analysis was performed 
using GraphPad Prism software for Windows version 5.0 
(GraphPad Software Inc., La Jolla, CA, USA).
Results
Isoform MacroH2A1.1 is downregulated in primary PCa
Relevant clinical and pathological data of patients 
included in this study is depicted in Table 1. MacroH2A1, 
MacroH2A1.1 and MacroH2A1.2 transcript levels were 
independently assessed in 15 MNPT, 45 PIN and 197 PCa 
tissue samples (Fig.  1a, Additional file  2: Table  S1). Age 
was not significantly different among the studied groups.
MacroH2A1 expression levels did not differ signifi-
cantly between MNPT and PCa, whereas a significant 
Table 1 Clinical and  pathological features of  subjects 
in each group of tissue samples
na not applicable, MNPT morphologically normal prostate tissue, PIN prostatic 
intraepithelial neoplasia, PCa prostate carcinoma
Clinicopathological features MNPT PIN PCa
Number of subjects, n 15 45 197
Age (years)
 Median (range) 64 (45–80) 64 (51–75) 64 (49–75)
PSA levels (ng/mL)
 Median (range) na na 8.3 (2.9–23)
Pathological stage
 pT2, n (%) na na 110 (55.8)
 pT3, n (%) 87 (44.2)
Gleason score [n (%)]
 6 na na 67 (34.0)
 7 115 (58.4)
 8 6 (3.0)
 9 9 (4.6)
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decrease was observed in PIN (p < 0.001) (Fig. 1a, Addi-
tional file  2: Table  S1). MacroH2A1.1 expression levels, 
however, differed significantly among the three groups 
[Kruskal–Wallis (KW) test, p < 0.001], with the lowest 
transcript levels found in PCa (p < 0.001 and p = 0.009, 
compared to MNPT and to PIN, respectively). Indeed, 
PIN lesions disclosed higher MacroH2A1.1 transcript 
levels than PCa, in cases in which PIN and matched 
tumor lesions from the same prostatectomy speci-
mens were available (Additional file  3: Fig. S1). Regard-
ing MacroH2A1.2, significantly lower expression levels 
were depicted for PIN comparing with MNPT and PCa 
(p < 0.001), whereas no significant differences were appar-
ent between MNPT and PCa.
Overall, PCa tissues showed higher MacroH2A1.1 
(1.33) than MacroH2A1.2 (0.59) relative expression 
levels, although the highest MacroH2A1.1 levels were 
observed in PIN lesions (2.39). Conversely, PIN lesions 
displayed the lowest levels of MacroH2A1.2 (0.06) 
(Fig. 1a, Additional file 2: Table S1).
H2AFY splicing regulators and H2AFZ expression 
in prostate cancer
To explain the altered ratio between H2AFY gene splicing 
variants, MacroH2A1 splicing regulators (QKI, DDX5 
and DDX17) transcription levels were also assessed in 
the same sample sets (Fig. 1b, Additional file 2: Table S1). 
A statistically significant downregulation of QKI and 
DDX17 was depicted for PCa (p < 0.001), whereas in PIN, 
DDX17 expression levels were significantly lower com-
pared to MNPT (p < 0.001). Concerning DDX5 expres-
sion, PIN demonstrated the lowest levels (p < 0.001, both 
for MNPT and PCa) but no significant differences were 
apparent between MNPT and PCa samples (Fig.  1b, 
Additional file 2: Table S1).
Fig. 1 Transcript levels of MacroH2A1 and splicing regulators in prostate tissue samples. a Transcriptional status of total MacroH2A1, MacroH2A1.1 
and MacroH2A1.2 isoforms in MNPT samples (n = 15), PIN lesions (n = 45) and PCa samples (n = 197), assessed by RT‑qPCR, and normalized with 
GUSB gene. b Transcript levels of three splicing regulators of H2AFY mRNA—QKI, DDX5 and DDX17—assessed by RT‑qPCR, and normalized with 
GUSB gene. MNPT morphologically normal prostate tissue, PIN prostatic intraepithelial neoplasia, PCa prostate carcinoma, KW Kruskal–Wallis test. 
Inter‑group analysis with Kruskal–Wallis test, followed by Dunn’s multiple comparisons test: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns not 
significant
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DDX5 transcript levels showed a stronger positive 
correlation with MacroH2A1 total expression (ρ = 0.51, 
p < 0.001), whereas a significant correlation was also 
found between QKI and MacroH2A1.1 splice variant 
expression levels (ρ = 0.56, p < 0.001). Splicing regulator 
DDX17 expression levels did not impressively correlate 
with any of the MacroH2A1 transcripts (Additional file 2: 
Table S2). Furthermore, no inverse correlation was found 
between H2AFY and H2AFZ transcript levels (Additional 
file 3: Fig. S2).
Diagnostic performance of MacroH2A1.1 and splicing 
regulators transcript levels in prostate tissues
Regarding associations with clinical-pathological vari-
ables, high MacroH2A1.1 expression levels signifi-
cantly associated with serum PSA levels above 10  ng/
mL (p < 0.01, (Additional file 3: Fig. S3). Moreover, Mac-
roH2A1.1 and QKI expression levels significantly associ-
ated with Gleason score (Fig. 2a), a clinical parameter of 
disease progression and reduced differentiation. Indeed, 
considering a two-tier categorization (Gleason score = 6 
vs. Gleason score > 6), higher grade (less differentiated) 
tumors displayed significantly reduced MacroH2A1.1 
(p < 0.01) and QKI (p < 0.001) expression levels. Consid-
ering a four-tier system, corresponding to the Gleason 
scores 6, 7 (3 + 4), 7 (4 + 3) and ≥ 8, differences among 
the four categories were found both for MacroH2A1.1 
and QKI expression (p = 0.0185 and p < 0.0001, respec-
tively; Additional file  3: Fig. S4). Pairwise analysis dis-
closed significant differences between Gleason scores 
6 and 7 (3 + 4) for MacroH2A1.1 and QKI expression 
(p = 0.0179 and p = 0.0082, respectively), and between 
Gleason scores 6 and ≥ 8 (p < 0.0001).
Receiver operator characteristic (ROC) curve 
analysis was performed to assess the ability of Mac-
roH2A1.1, DDX5, DDX17 and QKI expression levels 
in discriminating PCa from non-cancerous prostate 
tissues (Fig.  2b and Table  2). The empirical cut-off 
values were set to maximize sensitivity and specific-
ity. Remarkably, QKI outperformed MacroH2A1.1 and 
DDX5 and DDX17, displaying 88.8% sensitivity and 
93.3% specificity, corresponding to an area under the 
curve (AUC) of 0.94 (95% IC: 0.897-0.987); p < 0.0001 
(Table 2). Moreover, QKI presented a LR+ of 13.25 and 
a LR− of 0.12 (Table  2). Notwithstanding the limited 
number of normal tissue samples, a statistical model 
Fig. 2 Association of MacroH2A1.1 and QKI transcript levels with clinicopathological parameters and diagnostic performance. a Distribution of 
MacroH2A1.1 and QKI transcript levels in PCa cases, determined by RT‑qPCR and normalized with GUSB mRNA levels, according to categorized < 7 
(n = 68) and ≥ 7 (n = 129) Gleason score; Mann–Whitney U test: **p < 0.01, ****p < 0.0001. b ROC curves showing biomarker performance evaluation 
of MacroH2A1.1 (AUC = 0.92, 95% CI 0.876–0.965, p < 0.0001), DDX17 (AUC = 0.93, 95% CI 0.872–0.980, p < 0.0001), and QKI (AUC = 0.94, 95% CI 
0.897–0.987, p < 0.0001) transcript levels as discriminators of prostate cancer (PCa, n = 195) from morphological normal prostate tissue (MNPT, 
n = 15). AUC area under curve, CI confidence interval
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(1000 simulations) disclosed mean confidence interval 
range of 0.101, with 25% and 75% percentiles of 0.079 
and 0.119. Since the value obtained with the real data-
set was 0.089, we may consider that is within the range 
of expected values (Additional file 1: Data S1).
MacroH2A1 phenotypic impact in PCa cell lines
Transcript levels of MacroH2A1, respective isoforms 
and splicing regulators were assessed by RT-qPCR in five 
PCa cell lines (22Rv1, LNCaP, VCaP, DU145 and PC-3) 
and normalized for a benign prostate cell line (RWPE-1) 
(Fig. 3a, b).
Although 22Rv1 showed the highest MacroH2A1 
transcript levels, no significant differences were appar-
ent among PCa cell lines, comparing with RWPE-1. 
AR negative (AR−) PCa cell line DU145 displayed 
significantly higher MacroH2A1.1 expression levels 
than RWPE-1 (p < 0.05), whereas the lowest transcript 
levels of this variant were depicted for LNCaP, an AR 
positive (AR+) PCa cell line (p < 0.05). Concerning 
Table 2 Validity estimates for  MacroH2A1.1 and  QKI expression levels as  diagnostic biomarkers for  prostate cancer 
identification
Parameter MacroH2A1.1 performance DDX5 performance DDX17 performance QKI performance
Sensitivity (%) 80.7 82.7 47.3 88.8
Specificity (%) 93.3 93.3 93.3 93.3
Accuracy (%) 81.6 83.5 50.5 88.7
Positive likelihood ratio (LR+) 12.04 12.34 7.06 13.25











Fig. 3 Distribution of MacroH2A1 transcript and protein levels in prostate cancer cell lines. a Transcript levels of total MacroH2A1, MacroH2A1.1 and 
MacroH2A1.2, assessed by RT‑qPCR and normalized to GUSB mRNA levels, in androgen‑receptor positive RWPE‑1 benign prostate and 22Rv1, LNCaP 
and VCaP cancer cell lines, and in androgen‑receptor negative DU145 and PC‑3 prostate cancer cell lines. b Transcript levels of splicing regulators 
DDX5, DDX17 and QKI, assessed by RT‑qPCR and normalized to GUSB, in androgen positive and negative prostate cell lines. c Illustrative images of 
MacroH2A1 isoforms protein levels in prostate cancer cell lines and in non‑malignant prostate cell line RWPE‑1. d Fold variation of MacroH2A1.1 and 
MacroH2A1.2 protein levels, normalized to β‑actin, and directly compared to benign prostate cell line RWPE‑1. (mean ± SD, n = 3). Dunnet’s pairwise 
multiple comparisons test: *p < 0.05, **p < 0.01, ***p < 0.001
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MacroH2A1.2, all AR+ PCa cell lines (22Rv1, LNCaP 
and VCaP) displayed significantly higher expression 
levels than the benign prostate cell line (p < 0.01, for 
all) whereas AR− cancer lines did not disclose signifi-
cant differences compared to RWPE-1 (Fig.  3a). As to 
splicing regulators, among AR+ cell lines, only LNCaP 
depicted significantly higher DDX5 and DDX17 tran-
script levels than RWPE-1, whereas both AR− cells 
disclosed significantly higher DDX5, DDX17 and QKI 
mRNA level, cells except for QKI in DU145 (p < 0.05, 
Fig.  3b). Although no significant differences in global 
MacroH2A1 transcript levels between AR+ and AR− 
cancer cell lines were found, AR− cells depicted sig-
nificantly higher MacroH2A1.1 expression levels than 
AR+ cells, whereas the opposite was found for Mac-
roH2A1.2 (Additional file  3: Fig. S5a). Nonetheless, 
among splicing regulators, significant differences in 
splicing regulators expression levels between AR+ and 
AR− were only found for QKI (Additional file  3: Fig. 
S5b).
Concerning protein expression, MacroH2A1.1 and 
MacroH2A1.2 protein levels were also rather variable 
among cell lines (Fig.  3c, d). MacroH2A1.1 protein 
expression pattern only differed from transcript lev-
els in VCaP and DU145 cell lines, whereas for Mac-
roH2A1.2, protein levels in PCa cell lines followed 
the same trend of the transcript. Interestingly, Mac-
roH2A1.2 proteins levels were significantly higher in 
AR+ vs. AR− PCa cell lines (paralleling the findings at 
transcript level), whereas no differences were found for 
MacroH2A1.1 (Additional file 3: Fig. S5c).
To uncover the biological role of MacroH2A1, DU145 
cells were knockdown for this protein (Fig.  4a, b). 
Although reduced protein levels of both MacroH2A1 
variants (p < 0.05) was achieved, a more impressive 
effect was observed in MacroH2A1.2 (Fig.  4a, b). Phe-
notypically, increased cell viability was observed in 
MacroH2A1 knockdown DU145 cells at 48  h (p < 0.01) 
(Fig. 4c), whereas a significant decrease in apoptosis was 
apparent after 72 h, in the same cells (p < 0.05) (Fig. 4d).
Fig. 4 Knockdown of MacroH2A1 in DU145 cell line. a Illustrative images of MacroH2A1 isoforms protein after MacroH2A1 knockdown, carried out 
by si‑RNA, in DU145 prostate cancer cell line at 72 h’ post‑transfection, obtained by Western‑Blot. b Fold variation of MacroH2A1.1 and MacroH2A1.2 
protein levels in MacroH2A1‑knockdown DU145 cell line, in comparison to si‑scramble DU145 cell line (mean ± SD, n = 3), assessed by western‑blot. 
Unpaired t test: *p < 0.05. Impact of MacroH2A1 knockdown in cell viability (c) and apoptosis levels (d) after 72 h (mean ± SD, n = 3). Mann–Whitney 
U‑test: *p < 0.05, ***p < 0.001
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Additionally, MacroH2A1.1 isoform was ectopically 
overexpressed in LNCaP (cell line with the lowest levels) 
and specifically silenced in DU145 cells (cell line with 
the highest levels) (Fig. 5). Effective stable MacroH2A1.1 
overexpression (MacroH2A1.1OE) (Fig. 5a, b) and silenc-
ing (si-MacroH2A1.1) (Fig. 5e, f ) were confirmed at pro-
tein level. Indeed, MacroH2A1.1 protein levels almost 
doubled in MacroH2A1.1OE LNCaP cells (p < 0.05) 
and significantly associated with decreased cell viability 
(p < 0.001) (Fig.  5c), whereas apoptosis was significantly 
increased 72  h after transfection (p < 0.05) (Fig.  5d). 
Paradoxically, MacroH2A1.1 knockdown in DU145 also 
resulted in decreased cell viability (p < 0.001), with a 
concomitant increase in apoptosis (p < 0.001) (Fig. 5g, h, 
respectively).
As expected, both MacroH2A1.1 overexpressing and 
knockdown PCa cells did not show any effect on Mac-
roH2A1.2 protein levels (Fig. 5a, e).
Discussion
PCa is the most common malignancy in men and a lead-
ing cause of mortality and morbidity, worldwide. Both 
genetic and epigenetic disruption has been implicated in 
its initiation and progression. Unravel the mechanisms 
underlying tumor development are key to provide a more 
profound insight into PCa biology, which might translate 
into better diagnostic and prognostic tools, and the iden-
tification of novel therapeutic targets [2].
Among epigenetic mechanisms, the replacement of 
canonical histones has been recently implicated in tum-
origenesis [7]. Indeed, the role of the two MacroH2A1 
isoforms have been investigated in cancer [22–26]. 
In particular, MacroH2A1.1 is mostly considered a 
tumor suppressor, inhibiting stem cell-like properties 
and counteracting the functions of MacroH2A1.2 [16, 
17]. Although its role has been previously investigated 
in other tumor models, no data is available for PCa, to 
the best of our knowledge. Thus, we aimed to assess the 
putative role of MacroH2A1 isoforms in PCa initiation 
and progression.
We found that MacroH2A1.1 transcript levels were 
downregulated in PIN and primary PCa, compared to 
normal prostate tissues. Notwithstanding the reduced 
number of normal prostate tissues included in this 
study, which should be construed as a limitation, our 
results are in line with previous observations on Mac-
roH2A1.1 expression in other primary cancers [26, 32] 
and the intermediate expression levels depicted in PIN 
is consistent with its PCa precursor condition. How-
ever, MacroH2A1.2 expression levels did not parallel the 
upregulation reported for other tumors [25, 26]., as no 
significant differences were observed between PCa and 
normal tissues. Contrarily, prostate cancer precursor 
lesion (PIN), displayed significantly lower MacroH2A1.2 
transcript levels than those of MNPT and PCa. Interest-
ingly, it was recently demonstrated that MacroH2A1.2 
attenuates osteoclastogenesis in a PCa in  vitro model 
[33], but no direct comparisons with our results can be 
made as we only studied organ confined PCa.
Regarding, MacroH2A1 levels, albeit PIN displayed the 
lowest compared to MNPT and PCa, this was mostly due 
to MacroH2A1.2 downregulation. Indeed, MacroH2A1.1 
expression levels were lower in PCa comparing to MNPT. 
Thus, our results suggest that sustained MacroH2A1.1 
downregulation is associated with the emergence of the 
malignant phenotype in the prostate, whereas concomi-
tant MacroH2A1.2 decreased expression might be rel-
evant for the development of PIN lesions only, which 
frequently do not seem to progress into invasive car-
cinoma. Nevertheless, MacroH2A1 downregulation is 
likely to play a role along prostate tumorigenesis, sugges-
tive of a tumor suppressive effect.
Because an inverse correlation between MacroH2A1 
and H2A.Z has been suggested in previous studies [29], 
we assessed the transcript levels of the latter in our data-
set, as well, but no correlation was found between tran-
scripts levels of those two histone variants. Considering 
these findings, we hypothesized that differential expres-
sion of MacroH2A1 isoforms may be related with altered 
expression of its splicing regulators, specifically QKI, 
DDX5 and DDX17. Remarkably, in primary tumors, 
Fig. 5 Expression modulation of MacroH2A1.1 isoform in PCa cell lines. a Illustrative images of MacroH2A1 isoforms protein and β‑actin protein 
in MacroH2A1.1 transfected LNCaP cell line  (LNCaPMacroH2A1.1OE) and transfected control cell line  (LNCaPempty vector) at 72 h post‑transfection. b Fold 
variation of MacroH2A1.1 and MacroH2A1.2 protein levels in  LNCaPMacroH2A1.1OE, compared to  LNCaPempty vector (mean ± SD, n = 3). Unpaired t test: 
*p < 0.05, ns = not significant. Impact of MacroH2A1.1 overexpression in cell viability (c) and apoptosis levels (d) after 72 h (mean ± SD, n = 3). 
Mann–Whitney U‑test: *p < 0.05, ***p < 0.001. e Illustrative images of MacroH2A1 isoforms protein after MacroH2A1.1 knockdown, carried out by 
si‑RNA, in DU145 prostate cancer cell line at 72 h’ post‑transfection, obtained by Western‑Blot. f Fold variation of MacroH2A1.1 and MacroH2A1.2 
protein levels in MacroH2A1.1‑knockdown DU145 cell line, in comparison to si‑scramble DU145 cell line (mean ± SD, n = 3), assessed by 
western‑blot. Unpaired t test: *p < 0.05. Impact of MacroH2A1.1 knockdown in cell viability (g) and apoptosis levels (h) after 72 h (mean ± SD, n = 3). 
Mann–Whitney U‑test: *p < 0.05, **p < 0.01, ***p < 0.001
(See figure on next page.)
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variations in QKI and DDX17 expression levels paral-
leled those of MacroH2A1.1, whereas DDX5 transcript 
levels followed the same pattern of MacroH2A1 and 
MacroH2A1.2. Statistical analysis showed a moderately 
positive correlation between QKI and MacroH2A1.1, 
as well as between DDX5 and MacroH2A1 and its iso-
forms. Thus, we might speculate whether variations in 
MacroH2A1 isoforms expression in PCa is due to altered 
expression of its splicing regulators, although other, yet 
unidentified, factors might be involved, as well. In sup-
port of this hypothesis, QKI has been considered a tumor 
suppressor in various cancers and frequently associated 
with MacroH2A1.1 downregulation [21]. Concerning 
DDX5 and DDX17 expression, our results are some-
what unexpected as both are considered highly homol-
ogous oncogenic RNA-helicases [34]. Nevertheless, 
lower expression of both DDX5 and DDX17 has been 
reported in in  situ breast cancer, along with increased 
MacroH2A1.1/MacroH2A1.2 ratios [22]. Remarkably, 
this parallels our observations in PIN lesions, which are 
considered pre-invasive forms of PCa. Interestingly, 
DDX5, but not DDX17, affect key cellular pathways, 
including upregulation of AR in PCa and induction of 
epithelial-mesenchymal transition (EMT), a feature that 
is associated with tumor invasion capabilities [22, 35, 36]. 
Interestingly, we found significant differences in Mac-
roH2A1.1, MacroH2A1.2 and QKI, but not DDX5 and 
DDX17, transcript levels between AR+ and AR− PCa 
cell lines. Indeed, whereas the association between Mac-
roH2A1.1 and QKI expression found in primary PCa tis-
sues seems to hold true for PCa cell lines, the same was 
not evident for DDX5 and DDX17. Importantly, at pro-
tein level, significant differences between AR+ and AR− 
were found only for MacroH2A1.2, suggesting that other 
factors are involved in expression regulation of the iso-
forms. Nonetheless, because our series of primary PCa 
only represent hormone-therapy-naïve tumors, no defin-
itive conclusions can be made and a comparative study 
with castration-resistant PCa cases may further elucidate 
these findings.
Subsequently, we focused our attention on QKI and 
MacroH2A1.1 expression in a subset of cases with 
matched PIN and PCa tissues. Although paired lesions 
were found in the same gland, a direct causal link 
between them should not be construed. Nevertheless, 
this analysis might elucidate how QKI and MacroH2A1.1 
expression is altered along the carcinogenic process in 
the prostate gland. In approximately two-thirds of these 
cases, both QKI and MacroH2A1.1 expression was lower 
in PCa samples compared to matched PIN, a finding that 
parallels the observed variations in the whole case series. 
Moreover, this result further supports a causal role for 
QKI downregulation in MacroH2A1.1 decreased expres-
sion along prostate tumorigenesis. Indeed, decreased 
QKI and MacroH2A1.1 expression levels are clearly 
associated with PCa, as demonstrated by its ability to 
discriminate cancerous from non-cancerous prostate tis-
sues, notwithstanding the limited number of the latter 
samples (n = 15).
Some interesting associations between QKI and Mac-
roH2A1.1 expression and clinicopathological parameters 
were depicted. Specifically, PCa with higher Gleason 
score (i.e., less differentiated) displayed lower QKI and 
MacroH2A1.1 levels. Concerning MacroH2A1.1 expres-
sion, the same has been reported for other carcinomas, 
being its loss associated with worse outcome in colon 
cancer patients [26]. Conversely, MacroH2A1.1 expres-
sion was higher in PCa patients with higher serum 
PSA levels at diagnosis. Eventually, a comparison based 
on the basic Gleason patterns (3, 4 or 5) instead of the 
Gleason score might be considered more biologically 
relevant. However, we should emphasize that statistical 
associations were evaluated between clinicopathologi-
cal parameters and molecular data, and, in this regard, 
the meaningful comparison is among Gleason scores 
and not Gleason grades, as the latter are only used as a 
basis for Gleason score [30]. Moreover, Gleason grade 3, 
4 or 5 tumor areas are frequently intermingled and are 
not easily discriminated in tumors with mixed grades. 
Thus, an attempt to selectively collect those areas would 
most likely result in “contamination” and consequent 
analysis bias. On the other hand, if only 3 + 3, 4 + 4 and 
5 + 5 tumors would be analyzed, most of tumors, which 
are Gleason score 7 (3 + 4 or 4 + 3) would be excluded. 
Moreover, the procedure used for selectively identify-
ing the index tumor assured that the tumor area selected 
for molecular analyses was representative of the index 
tumor. Although the association with the Gleason score 
seems intuitive as higher scores correspond to less differ-
entiated and more aggressive PCa, the association with 
serum PSA levels, on the contrary, is almost counterin-
tuitive. Nevertheless, it should be recalled that cells from 
less differentiated PCa produce less PSA, which might 
have a negative impact on global serum PSA levels not-
withstanding heavy disease burden and corresponding 
poor outcome [37]. Overall, these findings suggest that 
lower QKI and MacroH2A1.1 expression levels might be 
associated with worse PCa-related survival, a hypothesis 
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that follows the same reported for other cancer mod-
els, but which requires further investigation in a larger 
cohort of PCa patients.
To further understand MacroH2A1 biological role in 
PCa, the phenotypic effect of MacroH2A1 silencing was 
evaluated in DU145 PCa cell line, which resulted in sig-
nificantly increased cell viability, paralleling previous 
observations in bladder cancer cells [17, 32]. Because 
in primary PCa MacroH2A1.1 levels predominate over 
those of MacroH2A1.2, we further assessed the phe-
notypic impact of its overexpression and silencing. In 
LNCaP cells, MacroH2A1.1 forced expression signifi-
cantly decreased cell viability and increased apoptosis, 
which is accordance with a putative tumor suppressive 
role [25, 26]. However, in DU145 cells, MacroH2A1.1 
knockdown disclosed opposite results to those of Mac-
roH2A1 knockdown in the same cells (which affected 
both isoforms, MacroH2A1.1 and MacroH2A1.2). Inter-
estingly, it was suggested that MacroH2A1 isoforms 
may have different effects [18, 27], since reduced Mac-
roH2A1.1 expression has been associated with a more 
aggressive phenotype [25, 26], whereas increased Mac-
roH2A1.1 correlated with poor prognosis in triple-neg-
ative breast cancer patients [23]. Thus, its putative role 
might be tumor model-dependent, since MacroH2A1.1 
might have an activating or repressive function depend-
ing on external cellular signals [38]. This may explain, 
at the least partially, our paradoxical finding in Mac-
roH2A1.1 silenced DU145 cells. Furthermore, the mod-
est silencing achieved for MacroH2A1.1 (only about 
50%), might have also contributed to that result.
Conclusions
In conclusion, this study is the first to report variations 
in expression of MacroH2A1 and its isoforms in prostate 
tissues, encompassing morphologically normal and neo-
plastic (both pre-invasive and invasive) lesions. Globally, 
we found that MacroH2A1.1 transcript levels gradually 
decrease during tumorigenesis, whereas MacroH2A1 and 
MacroH2A1.2 were downregulated only in PIN lesions. 
Interestingly, variations in MacroH2A1 are mostly 
affected by MacroH2A1.2 isoform and these alterations 
are associated with altered expression of splicing regula-
tors, specifically QKI for MacroH2A1.1, as well as DDX5 
for MacroH2A1 and isoforms ratios. Moreover, less dif-
ferentiated and more aggressive PCa cases display lower 
QKI and MacroH2A1.1 transcripts levels, as expected 
for putative tumor suppressors. Finally, the attenuation 
of malignant phenotype of PCa cell lines after manipula-
tion of Macro H2A1 expression, further suggest a tumor 
suppressor role for this histone variant, although Mac-
roH2A1.1 and MacroH2A1.2’s role in PCa require fur-
ther investigation.
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patients, assessed by RT‑qPCR and normalized to GUSB mRNA levels. Fig. 
S2. Correlation between MacroH2A1 and H2A.Z transcript levels in pros‑
tate cancer samples, assessed by RT‑qPCR and normalized to GUSB. Fig. 
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Gleason scores ≤ 6, 7 (3 + 4), 7 (4 + 3) and ≥ 8 prostate cancer tissue 
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MacroH2A1.1 and MacroH2A1.2, assessed by RT‑qPCR and normalized 
to GUSB mRNA levels, in androgen‑receptor positive prostate cancer 
cell lines (22Rv1, LNCaP and VCaP), and in androgen‑receptor negative 
prostate cancer cell lines (DU145 and PC‑3). (b) Distribution of transcript 
levels of splicing regulators DDX5, DDX17 and QKI, assessed by RT‑qPCR 
and normalized to GUSB, in androgen positive and negative prostate 
cancer cell lines. (c) Distribution of MacroH2A1.1 and MacroH2A1.2 protein 
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cancer cell lines. Mann–Whitney U‑test: **p < 0.01, ***p < 0.001. ns—non 
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